Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Placebo-Controlled, Sequential Single and Multiple Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral BT-11 in Healthy Adult Male and Female Volunteers

Next Previous
X
Search
Trial Profile

A Randomized, Placebo-Controlled, Sequential Single and Multiple Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral BT-11 in Healthy Adult Male and Female Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Omilancor (Primary)
  • Indications Crohn's disease; Ulcerative colitis
  • Focus Adverse reactions; First in man
  • Sponsors Landos Biopharma; NImmune Biopharma

    • Most Recent Events

    • 15 May 2019 Landos will present results at the 2019 Digestive Disease Week (DDW), as reported in a media release.
    • 15 May 2019 According to a Landos Biopharma media release, The publication was authored by company researchers , the Icahn School of Medicine at Mount Sinai and Royal Adelaide Hospital
    • 15 May 2019 According to a Landos Biopharma media release, full results published in Inflammatory Bowel Diseases Journal of the CrohnsColitisFn.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top